Drug Trial Radar · NCT06907875
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
May 8, 2025
Primary completion
Jul 7, 2027
Study completion Apr 30, 2032
Sponsor
- Lead sponsor
- Epicrispr Biotechnologies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are: How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working? Participants will receive a single dose of EPI-321 through a vein while being closely watched in a hospital and visit the clinic regularly for tests and checkups for about 5 years after getting EPI-321.
Conditions
- Facioscapulohumeral Muscular Dystrophy
Interventions
EPI-321Biological
EPI-321 IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of AEs and EPI-321 Related Adverse Reactions and Serious Adverse ReactionsTime frame: Baseline to up to 5 years.
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
David Geffen School of Medicine at University of California, Los Angeles
Los Angeles, California
Rare Disease Research
Atlanta, Georgia
Kennedy Krieger Institute, Center for Genetic Muscle Disorders
Baltimore, Maryland
University of Massachusetts Chan Medical School
Worcester, Massachusetts
Utah Program for Inherited Neuromuscular Disorders - University of Utah
Salt Lake City, Utah
Royal Alfred Hospital
Sydney, New South Wales, Australia
Pacific Clinical Research Network
Auckland, New Zealand, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.